Atezolizumab With Neoadjuvant Anti-Human Epidermal Growth Factor Receptor 2 Therapy and Chemotherapy in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Primary Results of the Randomized Phase III IMpassion050 Trial
Huober J, Zhang H, Restuccia E, Lambertini C, Gochitashvili N, Henschel V, Eiger D, Graupner V, Zhukova L, Pedrini J, Huggins-Puhalla S, Chang Y, Jarząb M, Niikura N, Barrios C, IMpassion050 Trial Investigators. Atezolizumab With Neoadjuvant Anti-Human Epidermal Growth Factor Receptor 2 Therapy and Chemotherapy in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Primary Results of the Randomized Phase III IMpassion050 Trial. J Clin Oncol 2022; 40:2946-2956.
Jun 28, 2022
Atezolizumab With Neoadjuvant Anti-Human Epidermal Growth Factor Receptor 2 Therapy and Chemotherapy in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Primary Results of the Randomized Phase III IMpassion050 Trial
Jun 28, 2022
J Clin Oncol 2022; 40:2946-2956
Huober Jens, Zhang Hong, Restuccia Eleonora, Lambertini Chiara, Gochitashvili Nino, Henschel Volkmar, Eiger Daniel, Graupner Vilma, Zhukova Lyudmila, Pedrini José, Huggins-Puhalla Shannon L, Chang Yuan-Ching, Jarząb Michał, Niikura Naoki, Barrios Carlos H, IMpassion050 Trial Investigators
more
